Islets of langerhans

Not to be confused with Langerhans cells, found in the epidermis.
Islets of Langerhans
Islet of Langerhans (mouse) in its typical proximity to a blood vessel; insulin in red, nuclei in blue.
Islets of Langerhans, hemalum-eosin stain.
Latin insulae pancreaticae




The islets of Langerhans are the regions of the pancreas that contain its endocrine (i.e., hormone-producing) cells. Discovered in 1869 by German pathological anatomist Paul Langerhans at the age of 22,[1] the islets of Langerhans constitute approximately 1% to 2% of the mass of the pancreas.

Anatomy and histology

There are about one million islets distributed throughout the pancreas of a healthy adult human,[2]:914 each of which measures about 0.2 mm in diameter.[2]:914 Each is separated from the surrounding pancreatic tissue by a thin fibrous connective tissue capsule which is continuous with the fibrous connective tissue that is interwoven throughout the rest of the pancreas.[2]:914 The combined mass of the islets is 1 to 1.5 grams.

Cell types

Hormones produced in the islets of Langerhans are secreted directly into the blood flow by (at least) five types of cells. In rat islets, endocrine cell subsets are distributed as follows:[3]

It has been recognized that the cytoarchitecture of pancreatic islets differs between species.[4][5][6] In particular, while rodent islets are characterized by a predominant proportion of insulin-producing beta cells in the core of the cluster and by scarce alpha, delta and PP cells in the periphery, human islets display alpha and beta cells in close relationship with each other throughout the cluster.[4][6]

Islets can influence each other through paracrine and autocrine communication, and beta cells are coupled electrically to other beta cells (but not to other cell types).

Paracrine feedback

The paracrine feedback system of the islets of Langerhans has the following structure:[7]

  • Insulin: activates beta cells and inhibits alpha cells
  • Glucagon: activates alpha cells which activates beta cells and delta cells
  • Somatostatin: inhibits alpha cells and beta cells

A large number of G protein-coupled receptors (GPCRs) regulates the secretion of insulin, glucagon and somatostatin from pancreatic islets,[8] and some of these GPCRs are the targets of drugs used to treat type-2 diabetes (ref GLP-1 receptor agonists, DPPIV inhibitors).

Electrical activity

Electrical activity of pancreatic islets has been studied using patch clamp techniques. It has turned out that the behavior of cells in intact islets differs significantly from the behavior of dispersed cells.[9]

Islet transplantation as a treatment for type 1 diabetes and insulin-requiring diabetes

Restoration of metabolic control via the transplantation of islets of Langerhans is an appealing approach. This can be achieved by transplantation of the pancreas as vascularized organ or of isolated pancreatic islets (islet cell clusters). Islet transplantation has emerged as a viable option for the treatment of insulin requiring diabetes in the early 1970s with steady progress over the last three decades.[10]

Islet transplantation has the possibility of restoring beta cell function from diabetes, offering an alternative to a complete pancreas transplantation or an artificial pancreas.

Because the beta cells in the islets of Langerhans are selectively destroyed by an autoimmune process in type 1 diabetes, clinicians and researchers are actively pursuing islet transplantation as a means of restoring physiological beta cell function in patients with type 1 diabetes.[11][12]

Recent clinical trials have shown that insulin independence and improved metabolic control can be reproducibly obtained after transplantation of cadaveric donor islets into patients with unstable type 1 diabetes.[12]

Islet transplantation for type 1 diabetes currently requires potent immunosuppression to prevent host rejection of donor islets.[13]

An alternative source of beta cells, such insulin-producing cells derived from adult stem cells or progenitor cells would contribute to overcoming the shortage of donor organs for transplantation. The field of regenerative medicine is rapidly evolving and offers great hope for the nearest future. However, type 1 diabetes is the result of the autoimmune destruction of beta cells in the pancreas. Therefore, an effective cure will require a sequential, integrated approach that combines adequate and safe immune interventions with beta cell regenerative approaches.[14]

Another potential source of beta cells may be xenotransplantation. The most likely source for xenogeneic islets for transplantation into human under evaluation is the pig pancreas. Interestingly, human and porcine insulin differ only for one amino acid, and insulin extracted from porcine pancreata has been used for the treatment of patients with diabetes before the development of recombinant human insulin technology. Several studies in small and large animals models have shown that transplantation of islet cells across species is possible. However, several problems need to be overcome for porcine islet transplantation to become a viable clinical option. The immunogenicity of xenogeneic tissues may be different from and even stronger than allogeneic tissues. For instance, Galalpha1-3Galbeta1-4GlcNAc (alpha galactosidase, alpha-Gal) expressed on porcine cells represents a major barrier to xenotransplantation being the target of preformed antibodies present in human blood.

Remarkable progress has been recorded in the development of genetically modified pigs lacking or overexpressing molecules that may improve acceptance of transplanted tissues across into humans. Pigs lacking alpha-Gal or overexpressing human decay accelerating factor (hDAF), amongst others, have been generated to study the impact on transplanted outcome in nonhuman primate models. Another possible antigenic target is the Hanganutziu-Deichter antigen, a sialic acid found in pigs and not humans, which may contribute to immunogenicity of porcine islets. Another limitation is the risk for transmission of zoonotic infections from pigs to humans, particularly from porcine endogenous retro-viruses (PERV). Amongst the approaches proposed to overcome islet xenorejection is immunoisolation of the clusters using encapsulation techniques that may shield them from immune attack. Studies in rodents and large animals have shown great promise that justify cautious optimism for the near future. Nonrandomized, uncontrolled pilot clinical trials are ongoing in subject with insulin-requiring diabetes to test the efficacy of encapsulation techniques to protect xenogeneic islets in the absence of chronic anti-rejection drugs.

Gallery

See also

References

External links

  • Karolinska Institutet, Sweden
  • Template:MeshNumber
  • "Pancreas, human – H&E", Blue Histology – Accessory Digestive Glands, School of Anatomy and Human Biology,

Template:System and organs

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.